Sonova Holding AG (SONVY) AI Stock Analysis

Sonova Holding AG

(Other OTC:SONVY)

Select Model

Rating:73Outperform

Price Target:$77.00▲(11.65% Upside)

Action:upgraded

Date:08/22/26

Sonova's overall score of 73 reflects a fundamentally strong company with robust profitability and cash generation, supported by a confident growth outlook and product innovation momentum. The primary strengths are the healthy financial position and positive earnings call guidance, which are partially offset by overbought technical signals and a stretched valuation. The recent revenue and FCF declines, along with Cochlear Implants headwinds, present near-term risks, but the company's market leadership and operational leverage provide a solid foundation.

Positive Factors

High profitability and cash conversionPersistently high gross and EBITDA margins indicate an attractive product mix and meaningful pricing power. Positive free cash flow and strong earnings conversion support internal investment, dividends, and resilience while preserving strategic flexibility over the next several quarters.

Negative Factors

Cochlear implant weaknessThe cochlear implant division is currently reducing group growth and profitability through lower system and upgrade volumes. Competitive pressure and the China slowdown make recovery dependent on a new processor and improved demand, leaving execution risk over the next two to six months.

Sonova Holding AG (SONVY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $20.42B
Dividend Yield: 1.68%
Average Volume (3M): 14.83K
Price to Earnings (P/E): 39.3
Beta (1Y): 0.88
Revenue Growth: 3.09%
EPS Growth: -11.75%
Country: US
Employees: 18,447
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Sonova Holding AG Business Overview & Revenue Model

Company Description

Sonova Holding AG is a prominent developer, manufacturer, and global distributor of hearing health solutions for all age groups. The company's operations are divided into two core areas: Hearing Instruments and Cochlear Implants. Its product range in...

How the Company Makes Money

Sonova makes money by selling hearing care products and services through two primary channels: (1) product sales to third-party providers and (2) direct-to-consumer sales through company-owned or affiliated retail clinics. 1) Hearing Instruments (hea...

Sonova Holding AG Earnings Call Summary

Earnings Call Date:May 17, 2026(Q4-2026)|% Change Since:53.60%|Next Earnings Date:Nov 11, 2026

Earnings Call SentimentPositive

The call highlights strong product-led sales momentum (notably in wholesale and select APAC markets), meaningful operating leverage, high cash conversion and disciplined capital allocation. Key short-term challenges are concentrated in the Cochlear Implants business (notably China) and several non‑core one-off charges plus FX headwinds. Management provided a confident but execution‑sensitive midterm roadmap (innovation, multi-channel expansion, operational savings) and reiterated growth and margin guidance for FY26/27.

Positive Updates

Strong Hearing Instruments Growth and Margin Expansion

Hearing Instruments segment sales rose 7.5% to CHF 3.4bn with growth accelerating to 7.9% in H2. Normalized EBITDA for the segment increased 17.3% to CHF 794m, delivering a 23.7% margin (up ~280 basis points in local currencies).

Negative Updates

Cochlear Implants Sales and Profit Pressure

Cochlear Implants sales declined 11% to CHF 252m (or -3.8% excluding China). System sales fell ~10% and upgrade sales declined 13%. Normalized EBITDA for CI was CHF 17.2m (margin ~6.8%), materially impacted by lower volumes and competitive pressure.

Company Guidance

Sonova guided FY 2026/27 to consolidated sales growth of 5–8% and core EBIT growth of 7–10% at constant exchange rates, assuming market growth of about 2–4% this year (trending toward a mid‑term 3–5% range); they expect wholesale to outpace the market, retail to deliver robust organic growth plus ~1–2% contribution from M&A and accelerated store openings, and Cochlear Implants to face H1 headwinds with a meaningful H2 pickup after a planned new processor launch. Management flagged modelling items: non‑core items of CHF 35–40m, M&A contribution to group sales ~1–2%, and FX as of early May 2026 that would reduce reported Swiss‑franc sales growth by ~1–2 percentage points and core EBIT growth in CHF by ~2–3 percentage points; H1 is expected to lie within the 7–10% core EBIT growth range.

Sonova Holding AG Financial Statement Overview

Summary

Sonova demonstrates strong profitability with a 73.7% gross margin and robust cash conversion (86% of net income to FCF). The balance sheet is healthy with a 0.66 debt-to-equity ratio and 20.8% ROE. However, recent revenue declined 5.3% and FCF fell 16.5%, indicating near-term pressure on top-line growth and earnings trends.

Income Statement

74Positive

Balance Sheet

82Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	3.57B	3.61B	3.87B	3.63B	3.74B	3.36B
Gross Profit	2.58B	2.66B	2.78B	2.62B	2.59B	2.42B
EBITDA	928.49M	930.70M	927.00M	921.70M	978.70M	960.90M
Net Income	427.14M	430.60M	540.50M	601.00M	647.50M	649.00M
Balance Sheet
Total Assets	5.63B	5.63B	5.92B	5.79B	5.55B	5.59B
Cash, Cash Equivalents and Short-Term Investments	722.10M	722.10M	687.10M	513.80M	414.80M	612.00M
Total Debt	1.71B	1.71B	1.76B	1.79B	1.81B	1.48B
Total Liabilities	2.99B	2.99B	3.24B	3.30B	3.32B	3.16B
Stockholders Equity	2.61B	2.61B	2.66B	2.47B	2.21B	2.41B
Cash Flow
Free Cash Flow	608.73M	626.10M	656.10M	624.70M	609.10M	815.90M
Operating Cash Flow	690.89M	707.50M	793.70M	753.30M	763.40M	922.50M
Investing Cash Flow	-197.38M	-192.20M	-212.70M	-234.00M	-429.50M	-707.00M
Financing Cash Flow	-428.51M	-452.90M	-401.80M	-415.30M	-523.50M	-1.37B

Sonova Holding AG Technical Analysis

Technical Analysis SentimentPositive

Last Price68.96

Price Trends

50DMA61.26Positive

100DMA56.95Positive

200DMA52.77Positive

Market Momentum

MACD2.36Negative

RSI77.05Negative

STOCH78.19Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONVY, the sentiment is Positive. The current price of 68.96 is above the 20-day moving average (MA) of 65.72, above the 50-day MA of 61.26, and above the 200-day MA of 52.77, indicating a bullish trend. The MACD of 2.36 indicates Negative momentum. The RSI at 77.05 is Negative, neither overbought nor oversold. The STOCH value of 78.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SONVY.

Sonova Holding AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SONVY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	74Outperform	$123.49B	23.60	10.60%	2.96%	9.77%	12.28%
SONVY	73Outperform	$19.82B	39.25	17.08%	1.68%	3.09%	-11.75%
ABT	69Neutral	$183.77B	39.33	9.12%	2.37%	10.00%	―
LIVN	69Neutral	$4.35B	22.89	15.41%	―	12.39%	―
INSP	63Neutral	$1.97B	14.61	17.62%	―	4.35%	161.83%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COCH	44Neutral	$51.31M	-0.98	1719.71%	―	-6.76%	42.70%

* Healthcare Sector Average

Performance Comparison

SONVY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SONVY	Sonova Holding Ag Unsponsored Adr	68.96	16.33	31.04%
ABT	Abbott Laboratories	106.20	-14.64	-12.11%
MDT	Medtronic	96.54	9.23	10.58%
LIVN	LivaNova PLC	78.97	26.39	50.19%
INSP	Inspire Medical	68.10	-5.61	-7.61%
COCH	Envoy Medical, Inc. Class A	6.63	-1.01	-13.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 22, 2026

Sonova Holding AG AI Stock Analysis